The Medicines Company
The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054
Phone: (973) 290-6000Website: https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-medicines-company-adding-potentially-first-class-investigational-cholesterol-lowering-therapy-inclisiran
Latest news
- FDA Approves Vabomere (meropenem and vaborbactam) for Complicated Urinary Tract Infections
29 August 2017 - The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance (meropenem-vaborbactam)
21 February 2017 - FDA Approves Antiplatelet Agent Kengreal (cangrelor) as Adjunct to Percutaneous Coronary Intervention
22 June 2015 - FDA Approves Raplixa (fibrin sealant [human]) to Control Bleeding During Surgery
30 April 2015 - FDA Approves New Formulation of Minocin (minocycline) for Injection
20 April 2015 - FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor
15 April 2015 - The Medicines Company Receives Complete Response Letter From FDA for Antiplatelet Agent Cangrelor
30 April 2014 - FDA Advisory Committee Recommends Against Antiplatelet Therapy Cangrelor
12 February 2014 - Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published
3 September 2013 - FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor
1 July 2013
